Ratings Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 29/11/2024			5-day change	1st Jan Change
46.59 ^CNY	+2.40%		+3.97%	-11.51%

11-12	Gan & Lee Pharmaceuticals Announces Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks	CI
11-11	Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults	CI

Summary: Gan & Lee Pharmaceuticals.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Highlights: Gan & Lee Pharmaceuticals.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses: Gan & Lee Pharmaceuticals.

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.96 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
The company is not the most generous with respect to shareholders' compensation.
Revenue estimates are regularly revised downwards for the current and coming years.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings Chart: Gan & Lee Pharmaceuticals.

Source: Surperformance

ESG chart: Gan & Lee Pharmaceuticals.

Source: Refinitiv

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	GAN & LEE PHARMACEUTICALS.				3.84B
	CSL LIMITED				89B
	SAMSUNG BIOLOGICS CO.,LTD.				49.64B
	UCB				37.1B
	BIOGEN INC.				23.41B
	INCYTE CORPORATION				14.37B
	BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.				12.74B
	BIOMARIN PHARMACEUTICAL INC.				12.58B
	ALTEOGEN INC.				10.67B
	CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.				9.71B
	Average				26.31B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

C+

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes